Mitogenic Signaling and the Relationship to Cell Cycle Regulation in Astrocytomas
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 51 (3) , 245-264
- https://doi.org/10.1023/a:1010657030494
Abstract
The activity and regulation of a number of mitogenic signaling pathways is aberrant in astrocytomas, and this is thought to play a crucial role in the development of these tumors. The cascade of events leading to the formation and the progression from low-grade to high-grade astrocytomas is well characterized. These events include activating mutations, amplification, and overexpression of various growth factor receptors (e.g. epidermal growth factor receptor (EGFR), platelet derived growth factor receptor (PDGFR), c-Met), signaling intermediates (e.g. Ras and Protein kinase C (PKC)), and cell cycle regulatory molecules (e.g. mouse double minute-2 (Mdm2), cyclin-dependent kinase-4 (CDK4), and CDK6), that positively regulate proliferation and cell cycle progression. Inactivating mutations and deletions of signaling and cell cycle regulatory molecules that negatively regulate proliferation and cell cycle progression (e.g. p53, p16/INK4a, p14/ARF, p15/INK4b, retinoblastoma protein (Rb), and Phosphatase and tensin homologue deleted from chromosome 10 (PTEN)) also participate actively in the development of the transformed phenotype. Several mitogenic pathways are also stimulated via an autocrine loop, with astrocytoma cells expressing both the receptors and the respective cognate ligand. Due to the multitude of factors involved in astrocytoma pathogenesis, attempts to target a single pathway have not given satisfactory results. The simultaneous targeting of several pathways or the targeting of signaling intermediates, such as Ras or PKC, situated downstream of many growth factor receptor signaling pathways may show more efficacy in astrocytoma therapy. We will give an overview of how the combination of these aberrations drive astrocytoma cells into a relentless proliferation and how these signaling molecules may constitute relevant therapeutic targets.Keywords
This publication has 100 references indexed in Scilit:
- Scatter Factor/Hepatocyte Growth Factor Expression Enhances Human Glioblastoma Tumorigenicity and GrowthBiochemical and Biophysical Research Communications, 1997
- Role of Mitogen-activated Protein Kinase Kinase in Regulation of the Epidermal Growth Factor Receptor by Protein Kinase CJournal of Biological Chemistry, 1996
- Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomasEuropean Journal Of Cancer, 1996
- Differential Modulation of Mitogen-activated Protein (MAP) Kinase/Extracellular Signal-related Kinase Kinase and MAP Kinase Activities by a Mutant Epidermal Growth Factor ReceptorJournal of Biological Chemistry, 1995
- Platelet‐derived growth factor in human gliomaGlia, 1995
- Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomasJournal of Neuro-Oncology, 1994
- Activated platelet‐derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell lineJournal of Cellular Physiology, 1994
- Prostaglandin F2α decreases the affinity of epidermal growth factor receptors in Swiss mouse 3T3 cells via protein kinase C activationFEBS Letters, 1992
- Protein kinase C isoforms in human glioblastoma cellsGlia, 1992
- Transforming growth factor-α, epidermal growth factor receptor, and proliferating potential in benign and malignant gliomasJournal of Neurosurgery, 1991